Lunit Expands AI-Powered Cancer Screening Solutions To France And Portugal

Lunit, a South Korean company at the forefront of AI-powered cancer diagnostics and therapeutics, has recently announced significant strides in its European expansion. The company has successfully secured two major commercial deals, partnering with TeleDiag in France and the Portuguese League Against Cancer (LPCC) to provide advanced radiology solutions aimed at detecting chest X-rays and breast cancer.

In a landmark move, Lunit has entered into a supply contract with TeleDiag, France's premier teleradiology group. This collaboration will see the implementation of Lunit INSIGHT CXR, a CE-marked AI solution capable of detecting ten common lung abnormalities, including lung cancer. TeleDiag, which was established in 2008, boasts a network of over 600 radiologists and serves more than 300 medical practices. Annually, it screens over 600,000 patients, making this partnership a significant advancement in integrating AI technology within the French healthcare system. Lunit was selected by TeleDiag after a comprehensive evaluation of various AI solutions for chest X-rays, standing out for its robust technical performance and comprehensive range of findings.

Simultaneously, Lunit has forged a supply agreement with the central region branch of LPCC to implement its FDA-cleared and CE-marked AI-powered mammography analysis solution, Lunit INSIGHT MMG. This initiative is set to analyze approximately 100,000 mammograms annually over the next three years. LPCC, established in 1941, is a pivotal non-profit organization overseeing the Portuguese National Breast Cancer Screening Program. The decision to adopt Lunit's solutions followed an extensive validation process using LPCC's own population screening data, where Lunit's technology demonstrated exceptional performance.

Brandon Suh, CEO of Lunit, expressed enthusiasm about these new partnerships: "Last week, we announced new supply contracts in East and Southeast Asia. This week, we unveil our new collaboration with TeleDiag and the Portuguese League Against Cancer in Europe; we're not just expanding our reach; we're transforming diagnostics globally," he stated. "Our aim is clear: to bring our AI-powered cancer screening solutions directly to healthcare providers, improving patient outcomes and ensuring that the benefits reach every corner of the world."

About Lunit: Founded in 2013, Lunit is on a mission to conquer cancer through deep learning-based medical AI. The company is dedicated to using AI for accurate diagnosis and optimal treatment for each cancer patient through AI-powered medical image analytics and AI biomarkers. With its flagship Lunit INSIGHT suite receiving FDA clearance and the CE Mark, it is now clinically used in approximately 3,000 hospitals and medical institutions across over 40 countries. Headquartered in Seoul, South Korea, Lunit continues to make its mark globally with offices and representatives worldwide. For more information on their innovative solutions and global impact, visit lunit.io.